Alto Neuroscience, Inc. (NYSE:ANRO) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC lessened its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 1.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 116,254 shares of the company’s stock after selling 1,762 shares during the quarter. Fred Alger Management LLC owned about 0.43% of Alto Neuroscience worth $1,243,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. RA Capital Management L.P. purchased a new stake in Alto Neuroscience during the 1st quarter worth approximately $21,267,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Alto Neuroscience in the first quarter worth $9,788,000. Vanguard Group Inc. purchased a new stake in shares of Alto Neuroscience during the first quarter worth $8,233,000. Jennison Associates LLC acquired a new stake in shares of Alto Neuroscience in the first quarter valued at $7,039,000. Finally, Artal Group S.A. purchased a new position in Alto Neuroscience in the first quarter valued at $5,372,000.

Insiders Place Their Bets

In other Alto Neuroscience news, insider Adam Savitz purchased 12,069 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was bought at an average cost of $12.60 per share, with a total value of $152,069.40. Following the acquisition, the insider now directly owns 36,920 shares of the company’s stock, valued at $465,192. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alto Neuroscience Stock Up 0.8 %

Shares of NYSE ANRO opened at $12.10 on Friday. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average of $12.00 and a two-hundred day moving average of $12.91. Alto Neuroscience, Inc. has a 1 year low of $7.91 and a 1 year high of $24.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. Research analysts anticipate that Alto Neuroscience, Inc. will post -2.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Rodman & Renshaw started coverage on Alto Neuroscience in a report on Friday, June 21st. They set a “buy” rating and a $43.00 price target on the stock. Wedbush restated an “outperform” rating and set a $29.00 target price on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Alto Neuroscience presently has a consensus rating of “Buy” and an average price target of $33.80.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.